North America Hemodialysis and Peritoneal Dialysis Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Type, Product, and End User

The hemodialysis and peritoneal dialysis market in North America is expected to grow from US$ 31,852.39 million in 2022 to US$ 45,277.56 million by 2028; it is estimated to grow at a CAGR of 6.0% from 2022 to 2028.

The rising prevalence of kidney diseases is the major factor driving the North America hemodialysis and peritoneal dialysis market. Chronic kidney disease (CKD) and acute kidney injury (AKI) are conditions in which the kidneys are damaged and cannot filter blood properly. Because of this, excess fluid and waste from blood remain in the body, which may cause other health problems such as heart disease and stroke. CKD usually worsens over time, even though treatment has shown slow progression. If CKD is left untreated, it can progress to kidney failure and early cardiovascular disease. In CKD, when the kidneys stop working, dialysis or kidney transplant is needed for survival. When treated with dialysis or kidney transplant, this kidney failure is called end-stage renal disease (ESRD). According to the Centers for Disease Control and Prevention (CDC), approximately 36 million adults are suffering from CKD in the US. Further, every 24 hours, 360 people begin dialysis treatment for kidney failure. In 2017, 697.5 million cases of CKD (all stages) were recorded worldwide, with a North American prevalence of 9.1%.

In the past few years, the requirement for dialysis has increased. For instance, according to the National Kidney Foundation, in 2018, 785,883 US residents faced kidney failure, of which 554,038 received dialysis. Likewise, according to the data published by the Food & Drug Administration (FDA), about 10,000 children in the US develop AKI. These children have a survival rate of around 38% to 43%.

The increasing prevalence of ESRD is also one of the major factors driving the market. For instance, according to the United States Renal Data System (USRDS), nearly 786,000 people in the country are living with end-stage kidney disease (ESKD), also known as end-stage renal disease (ESRD). Thus, the increasing prevalence of chronic kidney disease, acute kidney injury, and end-stage renal disease, which leads to the condition of dialysis, is driving the hemodialysis and peritoneal dialysis market.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America hemodialysis and peritoneal dialysis market. The North America hemodialysis and peritoneal dialysis market is expected to grow at a good CAGR during the forecast period.

North America Hemodialysis and Peritoneal Dialysis Market Segmentation

The North America hemodialysis and peritoneal dialysis market is segmented into type, product, end user, and country.

• Based on type, the market is bifurcated into hemodialysis and peritoneal dialysis. In 2022, the hemodialysis segment is expected to hold a larger market share.
• Based on product, the hemodialysis and peritoneal dialysis market is segmented into devices, consumables, and services. The services segment is likely to hold the largest market share in 2022.
• Based on end user, the market is segmented into hospital-based and home-based. The hospital-based segment is expected to account for a larger share in 2022.
• Based on country, the North America hemodialysis and peritoneal dialysis market is segmented into the US, Canada, and Mexico. The US is anticipated to hold the largest market share in 2022.

Asahi Kasei Medical Co., Ltd.; B. Braun Melsungen AG; Baxter International Inc.; DaVita Inc.; Dialife SA; Evoqua Water Technologies LLC. (Mar Cor Purification); Fresenius Medical Care AG & Co KGaA; Nipro Medical Corporation; and Rockwell Medical, Inc. are among the leading companies operating in the North America hemodialysis and peritoneal dialysis market.